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Abstract Adenosine triphosphate (ATP) is coreleased with
catecholamines from adrenal medullary chromaffin cells in
response to sympathetic nervous system stimulation and may
regulate these cells in an autocrine or paracrine manner.
Increases in extracellular signal-regulated kinase (ERK) 1/2
phosphorylation were observed in response to ATP stimula-
tion of bovine chromaffin cells. The signaling pathway
involved in ATP-mediated ERK1/2 phosphorylation was
investigated via Western blot analysis. ATP and uridine 5′-
triphosphate (UTP) increased ERK1/2 phosphorylation po-
tently, peaking between 5 and 15 min. The mitogen-activated
protein kinase (MAPK/ERK)-activating kinase (MEK) in-
hibitor PD98059 blocked this response. UTP, which is
selective for G-protein-coupled P2Y receptors, was the most
potent agonist among several nucleotides tested. Adenosine
5′-O-(3-thio) triphosphate (ATPγS) and ATP were also
potent agonists, characteristic of the P2Y2 or P2Y4 receptor
subtypes, whereas agonists selective for P2X receptors or
other P2Y receptor subtypes were weakly effective. The
receptor involved was further characterized by the nonspe-
cific P2 antagonists suramin and reactive blue 2, which each
partially inhibited ATP-mediated ERK1/2 phosphorylation.
Inhibitors of protein kinase C (PKC), protein kinase A
(PKA), Ca
2+/calmodulin-dependent protein kinase II (CaM-
KII), and phosphoinositide-3 kinase (PI3K) had no effect on
ATP-mediated ERK1/2 phosphorylation. The Src inhibitor
PP2, epidermal growth factor receptor (EGFR) inhibitor
AG1478, and metalloproteinase inhibitor GM6001 decreased
ATP-mediated ERK1/2 phosphorylation. These results sug-
gest nucleotide-mediated ERK1/2 phosphorylation is medi-
ated by a P2Y2 or P2Y4 receptor, which stimulates
metalloproteinase-dependent transactivation of the EGFR.
Keywords Extracellularsignal-regulatedkinase.
Phosphorylation.Epidermalgrowthfactorreceptor.
Transactivation.P2Y2 receptor.P2Y4 receptor.UTP
Abbreviations
BACC bovine adrenal chromaffin cells
ERK1/2 extracellular signal-regulated kinase 1 and 2
EGF epidermal growth factor
EGFR EGF receptor
MEK mitogen-activated protein kinase/ERK
kinase
[Ca
2+]i cytosolic free Ca
2+ concentration
PKC protein kinase C
PKA protein kinase A
CaMKII Ca
2+/calmodulin-dependent protein kinase II
PI3K phosphoinositide-3 kinase
2-MeSATP 2-methylthio ATP
α,β-
meATP
α,β-methylene ATP
HB-EGF heparin-binding EGF-like growth factor
Pyk2 proline-rich tyrosine kinase
SH3 Src homology 3
Introduction
Chromaffin cells are neuroendocrine cells that synthesize and
secrete catecholamines in response to sympathetic nervous
system stimulation and therefore participate in regulation of
stress-modified parameters such as heart rate and blood
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released along with the catecholamines from the chromaffin
granules,includingneuropeptidessuchastheenkephalinsand
adenosine triphosphate (ATP) [1]. In addition to being re-
leased into the circulation, these agents may regulate chro-
maffin cell activity in an autocrine or a paracrine manner,
allowing the cells to adjust to varying levels of stimulation.
The role of ATP in chromaffin cell function has not been
well defined, even though it is secreted in high concen-
trations from chromaffin cells [1]. It has been suggested
that ATP regulates chromaffin cell secretion, either posi-
tively [2] or negatively [3, 4], and that ATP regulates the
function of voltage-dependent calcium channels [5]. ATP
exerts its effects through either G-protein-coupled recep-
tors, designated P2Y; or ion channels, designated P2X.
These receptor types are further divided into subtypes,
including P2Y1, P2Y2, P2Y4,P 2 Y 6, and P2Y11–14 for the
G-protein-coupled P2Y receptors and P2X1–7 for those that
activate ion channels [6]. Previous work with chromaffin
cells indicated ATP stimulation results in increases in
inositol phosphates [7], cyclic adenosine monophosphate
(cAMP) [8], and [Ca
2+]i accumulation [7], likely via
activation of a P2Y2 or P2Y4 receptor, both of which are
present in bovine chromaffin cells (unpublished observa-
tions). The downstream effects of P2Y receptor stimulation
by ATP in chromaffin cells are not known. The observed
increases in signaling messengers may bring about the
activation of multiple protein kinases or tyrosine kinases.
In several cell types, ATP signaling has been shown to
activate extracellular signal-regulated kinase 1 and 2 (ERK1/
2). P2Y receptors have been shown to couple to ERK1/2
activation via activation of protein kinases such as phosphoi-
nositide-3 kinase (PI3K) [11] or protein kinase C (PKC) [10,
11]. P2Y receptor-mediated ERK1/2 has also been shown to
be dependent on activation of tyrosine kinases such as Src or
proline-rich tyrosine kinase (Pyk2) [9, 10] and/or on trans-
activation of the epidermal growth factor receptor (EGFR)
[9]. Additionally, increases in cAMP in response to ATP may
result in activation of protein kinase A (PKA), which has
been shown to activate ERK1/2 [12]. Increases in [Ca
2+]i in
response to ATP may result in activation of Ca
2+/calmodulin-
dependent protein kinase II (CaMKII), which has also been
shown to phosphorylate ERK1/2 [13]. Therefore, we elected
to examine ATP-mediated ERK1/2 phosphorylation and the
receptor subtype and signaling mechanism present in bovine
chromaffin cells.
Materials and methods
Chromaffin cell isolation and cell culture Bovine adrenal
chromaffin cells (BACC) were isolated using a collagenase
perfusion method as described previously [14, 15]. Cells
were maintained on six-well plates at a density of 3×10
6
cells/well at 37°C with 5% CO2. Viability and purity were
verified to be >95% by Trypan blue exclusion and neutral
red staining, respectively.
Western blot analysis Cells were incubated with agonist for
10 min, and inhibitor preincubations were 15 min, unless
otherwise indicated. Cells were rinsed with phosphate
buffered saline (PBS) and lysed with 200 μlo f5 0m M
N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
(HEPES) (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid), pH 7.2, containing 1 mM ethylenediaminetetraacetate
(EDTA), 1 mM ethyleneglycoltetraacetic acid (EGTA),
0.2% triton X-100, 10 mM β-glycerol 2-phosphate diso-
dium salt, 1 mM sodium orthovanadate, 1 mM benzami-
dine, 4 μg/ml leupeptin, 1 μM microcystin-LR, and
0.5 mM DTT. Lysates were centrifuged at 13,000 g, and
protein concentrations of supernatants were determined
with the Bio-Rad protein assay (Bio-Rad, Hercules, CA,
USA). Loading buffer (2X) was added to cell lysates,
consisting of 125 mM Tris(hydroxymethyl)aminomethane
HCl (Research Organics, Cleveland, OH, USA), 4%
sodium dodecylsulfate (SDS) (Research Organics, Cleve-
land, OH, USA), 20% glycerol, and 0.02% bromophenol
blue. Samples were subsequently boiled and subjected to
SDS-polyacrylamide gel electrophoresis (PAGE) on 10%
Tris-HCl Criterion gels (BioRad, Hercules, CA, USA).
Protein was transferred to fluorescent-polyvinylidene
fluoride (PVDF) membranes (Millipore, Billerica, MA,
USA). Membranes were next blocked in Odyssey blocking
buffer (LI-COR Biosciences, Lincoln, NE, USA) for 1 h,
then incubated in Odyssey blocking buffer containing 0.2%
Tween 20 (polyoxyethylene-sorbitan monolaurate) and
mouse-anti-phospho-ERK 1/2 (Thr
202/Tyr
204) and rabbit-
anti-ERK 1/2 (Cell Signaling Technology, Boston, MA,
USA) primary antibodies. Blots were then incubated in
Odyssey blocking buffer with 0.2% Tween 20 and 0.02%
SDS and with the secondary antibodies goat-anti-mouse
immunoglobulin (Ig)G Alexa Fluor680 (Molecular Probes,
Eugene, OR, USA) and goat-anti-rabbit IgG IR800 (Rock-
land Immunochemicals, Gilbertsville, PA, USA). Mem-
branes were developed with the Odyssey Infrared Imaging
System, which utilizes two infrared channels (700 nm and
800 nm), allowing for detection of two target proteins
simultaneously, in this case phosphorylated and total
ERK1/2.
Statistics Band integrated intensities were determined with
Odyssey Imaging software. Phospho-ERK1/2 intensities
were divided by total ERK1/2 intensities and normalized to
fold increases over control. Data were analyzed with
GraphPad Prism software, and one-way analysis of vari-
ance (ANOVA) was utilized to determine statistical signif-
324 Purinergic Signalling (2008) 4:323–330icance. The decision was made to utilize ERK2 for
graphical representations, as band intensities for phosphor-
ylated ERK2 were stronger than phosphorylated ERK1,
though results obtained were quantitatively similar for
both.
Chemicals Nucleotides and analogs were obtained from
Sigma-Aldrich (St. Louis, MO, USA). PD98059 (2′-amino-
3′-methoxylflavone), PMA (phorbol12-myristate 13-acetate),
suramin, and reactive blue 2 (RB2) were also obtained
from Sigma-Aldrich. NF279 [8,8′-[Carbonylbis(imino-4,1-
phenylenecarbonylimino-4,1-phenylenecarbonylimino)]bis-
1,3,5-naphthalenetrisulfonic acid hexasodium salt] was pur-
chased from Tocris (St. Louis, MO, USA). KT5720
[(9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-9-
methyl-1-oxo-9, 12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]
pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid hexyl
ester], Ro-31–8220 [2-[1-(3-(Amidinothio)propyl)-1H-
indol-3-yl]-3-(1-methylindol-3-yl)maleimide methanesulfo-
nate], LY294002 ]2-(4- morpholinyl)-8-phenyl-4H-1-
benzopyran-4-one], PP1 [4-amino-5-(4-methylphenyl)-7-
(t-butyl)pyrazolo-D-3,4-pyrimidine], PP2 [4-amino-5-(4-
chlorophenyl)-7-(t-butyl)pyrazolo-D-3,4-pyrimidine],
AG1478 [4-(3-Chloroanilino)-6,7-dimethoxyquinazoline],
and GM6001 [N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-
methylpentanoyl]-L-tryptophan methylamide] were pur-
chased from Biomol (Philadelphia, PA, USA). Bis-I (bisindo-
lylmaleimide-I), KN-92 [2-[N-(4-methoxybenzenesulfonyl)]
amino-N-(4-chlorocinnamyl)- N-methylbenzylamine], KN-
93 [2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]
amino-N-(4-chlorocinnamyl)-N-methylbenzylamine], and
wortmannin were purchased from Merck-Calbiochem Bio-
sciences (Darmstadt, Germany). H89 [N-[2-(p-Bromocinna-
mylamino)ethyl]-5-isoquinolinesulfonamide] was obtained
from Upstate (Charlottesville, VA, USA).Other reagents were
obtained from either Sigma-Aldrich or Fisher Scientific.
Results
Western blot analyses with antibodies specific to activated
ERK1/2 phosphorylated at Thr
202/Tyr
204 were utilized to
examine the time course of ERK1/2 phosphorylation in
response to nucleotide stimulation. Both ATP and UTP
potently increased ERK1/2 phosphorylation, with a peak
between 5 and 15 min (Fig. 1). ERK1/2 has been shown to
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Fig. 1 Nucleotide-stimulated ERK1/2 phosphorylation is time depen-
dent. BACCs were treated with ATP (100 μM) or UTP (100 μM) for 2
to 30 min. Blots are representative of three independent experiments
performed in triplicate (n=3); the upper band (phosphorylated or
nonphosphorylated) is ERK1=44 kDa, and the lower band is ERK2=
42 kDa. Blot intensities were measured with the Odyssey Imaging
System; values are phosphorylated ERK2 intensity divided by total
ERK2 intensity. Points on the graph represent mean ± standard error
of the mean
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Fig. 2 MEK inhibition decreases ATP- and UTP-mediated ERK1/2
phosphorylation. BACCs were treated with PD98059 (10 μM) or
dimethylsulfoxide for 15 min, followed by a 10-min stimulation with
ATP (100 μM) or UTP (100 μM). Blots are representative of three
independent experiments performed in triplicate (n=3); the upper
band (phosphorylated or nonphosphorylated) is ERK1=44 kDa and
the lower band is ERK2=42 kDa. Blot intensities were measured with
the Odyssey Imaging System; values are phosphorylated ERK2
intensity divided by total ERK2 intensity. Bars on the graph represent
mean ± standard error of the mean. *** p<0.001 vs. stimulator alone
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PD98059 was utilized to confirm the immediate upstream
signaling event responsible for nucleotide-mediated ERK1/
2 phosphorylation. PD98059 (10 μM) significantly de-
creased both ATP-mediated (∼90%) and UTP-mediated
(∼70%, Fig. 2, Table 1) ERK1/2 phosphorylation.
Most studies designed to determine purinergic receptor
subtypes use ligand potency studies due to the lack of
available highly selective receptor subtype antagonists [16].
Correspondingly, we used a similar approach to character-
ize the receptor subtype involved in ERK1/2 phosphoryla-
tion. Examination of several purine analogs revealed a rank
order of potency of UTP (EC50=1.6 μM)>ATPγS
(6.5 μM)≥ATP (13 μM)>uridine diphosphate (UDP)
(120 μM) = adenosine diphosphate (ADP) (220 μM)= 2-
methylthio (ATP)2-MeSATP (320 μM)>>α,β-methylene
ATP (α,β-meATP) (Fig. 3), consistent with the involve-
ment of a P2Y2 or P2Y4 receptor, as both UTP and ATP
exhibit strong agonist action.
The involvement of a P2 receptor in ERK1/2 phosphor-
ylation was further supported using the nonselective P2
receptor antagonists suramin and RB2. Suramin (100 μM)
significantly decreased ATP- or UTP-mediated ERK1/2
phosphorylation (∼60%, Fig. 4, Table 1). RB2 (100 μM)
also decreased the effect of ATP- or UTP-stimulation on
ERK1/2 phosphorylation (∼35%, Fig. 4, Table 1). The P2X-
specific receptor agonist α,β-meATP had no effect on
ERK1/2 phosphorylation at concentrations up to 100 μM
(Fig. 3), eliminating the involvement of several of the P2X
receptor subtypes. Moreover, UTP is selective for P2Y
receptors, precluding the involvement of a P2X receptor in
nucleotide-mediated ERK1/2 phosphorylation.
ATP stimulation of chromaffin cells has been shown to
increase inositol phosphates [7], cAMP [8], and [Ca
2+]i
accumulation [7], which may lead to activation of several
protein kinases, which may in turn be involved in ATP-
mediated phosphorylation of ERK1/2. Therefore, a variety
of inhibitors were used to examine which kinases are
involved in ATP-mediated ERK1/2 phosphorylation. The
PKA inhibitors H89 (10 μM) and KT5720 (100 nM) had
no effect on ATP- or UTP-mediated ERK1/2 phosphoryla-
tion (Table 1). The broad-spectrum PKC inhibitors Ro-31–
8220 (10 μM) and Bis-I (3.5 μM) also had no effect on
ATP- or UTP-mediated ERK1/2 phosphorylation, although
they were capable of blocking PMA-mediated ERK1/2
phosphorylation (∼60%, Table 1). Moreover, the CaMKII
inhibitor KN93 (1 μM) and the PI3K inhibitors wortmannin
(300 nM) and LY294002 (20 μM) had no effect on ATP- or
UTP-mediated ERK1/2 phosphorylation (Table 1).
In addition to activation of PKs, P2Y receptors may
utilize tyrosine kinases to activate ERK1/2 [10]. Therefore,
the tyrosine kinase inhibitor PP2 was used to examine the
role of Src family members in ATP-mediated ERK1/2
phosphorylation. PP2 (1 μM) decreased ATP- or UTP-
mediated ERK2 phosphorylation (∼40%, Fig. 5, Table 1).
In addition to inhibiting Src family members, PP2 is also a
weak inhibitor of the EGFR. Also, G-protein-coupled
receptor activation of Src family members may result in
Table 1 Involvement of signaling pathways in ATP- and UTP-mediated ERK1/2 phosphorylation
Inhibitor/antagonist ATP UTP
ERK1 ERK2 ERK1 ERK2
P2R Suramin (100 μM) 61.8±3.1*** 54.7±3.8*** 62.0±5.7*** 62.0±5.7***
Antagonists RB2 (100 μM) 32.3±4.5*** 29.5±4.5*** 44.9±10.7*** 44.9±9.1***
MEK inhibitor PD98059 (10 μM) 95.3±5.3*** 94.4±4.5*** 69.5±3.4*** 64.3±4.2***
PKC inhibitors Bis-I (3.5 μM) 12.7±20.5 4.6±7.9 5.2±12.9 −1.3±10.4
Bis-I-PMA 76.1±2.9*** 67.5±3.2*** ––
Ro-31-8220 (10 μM) −40.0±28.8 −13.5±10.2 −13.4±14.9 −8.7±10.9
Ro-31-8220-PMA 66.6±2.6*** 54.4±2.3*** ––
PKA inhibitors H89 (10 μM) −67.1±36.3 −42.4±14.4 −27.5±31.4 −16.4±16.5
KT5720 (100 nM) −1.5±13.3 −1.9±16.5 1.9±13.9 6.5±13.2
CaMKII inhibitor KN93 (1 μM) 22.5±27.2 7.1±12.7 −20.1±18.2 −14.2±15.4
PI3K inhibitors Wortmannin
(300 nM)
−10.0±34.2 −3.9±15.7 10.0±25.9 12.5±14.6
LY294002 (20 μM) −3.9±15.7 1.0±17.4 18.6±18.7 30.3±12.1
Src inhibitor PP2 (1 μM) 40.9±16.1* 39.5±9.1*** 46.0±8.1*** 32.4±9.6***
EGFR inhibitors AG1478 (2.6 μM) 73.7±2.0*** 71.1±2.3*** 62.9±7.2*** 69.6±6.7***
MMP inhibitors GM6001 (2.5 μM) 69.2±5.8** 60.8±7.1*** 66.7±10.1*** 62.0±10.4***
Cells were pretreated with inhibitors for 15 min then stimulated with 100 μM UTP (or 1 μM PMA) for 10 min. Values are percent inhibition of
UTP-mediated ERK1/2 phosphorylation ± standard error of the mean for three experiments in triplicate. Bis-I-PMA and Ro-31-8220-PMA refer
to using PMA as the stimulator rather than UTP
*p<0.05 vs. stimulator alone,**p<0.01 vs. stimulator alone, **p<0.001 vs. stimulator alone
326 Purinergic Signalling (2008) 4:323–330activation of ERK1/2 via activation of Ras [17, 18] or via
transactivation of the EGFR. Therefore, the involvement of
EGFR in ATP-mediated ERK1/2 phosphorylation was
determined by treating cells with the EGFR inhibitor
AG1478 (2.6 μM), which decreased ATP- and UTP-
mediated ERK2 phosphorylation by about 70% (Fig. 6a,
Table 1). EGF-mediated ERK1/2 phosphorylation was
completely blocked by AG1478 (100%, p<0.001, data not
shown). Transactivation of the EGFR by G-protein-coupled
receptors may be mediated by tyrosine kinases such as Src
or via metalloproteinases, which release EGFR ligands such
as heparin-binding EGF-like growth factor (HB-EGF) from
the cell membrane [19]. The metalloproteinase inhibitor
GM6001 (2.5 μM) decreased ATP- and UTP-mediated
ERK1/2 phosphorylation by about 65% (Fig. 6b, Table 1).
Discussion
ATP and UTP potently increase ERK1/2 phosphorylation,
with a peak between 5 and 15 min. This rapid peak in
ERK1/2 phosphorylation in response to ATP would allow
the cells to respond quickly to varying levels of stimulation.
Although the physiological effects of ERK1/2 phosphory-
lation in these cells are unknown, possible actions requiring
a rapid response include either the acute activation of
proteins involved in catecholamine secretion and/or stimu-
lation of protein expression important for exocytosis.
Ligand potency and inhibitor studies suggest either the
P2Y2 or P2Y4 receptor subtype is responsible for nucleo-
tide-mediated ERK1/2 phosphorylation, similar to data
obtained for increases in inositol phosphates (unpublished
observations). Both of these receptor subtypes are present
in chromaffin cells, based on reverse transcriptase real-time
polymerase chain reaction (PCR) data for P2Y2 and P2Y4,
and appear to be expressed in these cells according to
Western blot analysis with specific antibodies (unpublished
Con
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100 nM 1 µM3   µM 10 µM 30 µM 100 µM 1 mM
ATP
Overlay
Fig. 3 P2Y2 or P2Y4 receptor activation increases ERK1/2 phos-
phorylation. BACCs were treated with increasing concentrations of
nucleotides and analogs for 10 min. Blots are representative of three
independent experiments performed in triplicate (n=3); the upper
band (phosphorylated or nonphosphorylated) is ERK1=44 kDa, and
the lower band is ERK2=42 kDa. Blot intensities were measured with
the Odyssey Imaging System; values are phosphorylated ERK2
intensity divided by total ERK2 intensity. Points on the graph
represent mean ± standard error of the mean. Con (control) refers to
results obtained with unstimulated cells
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Fig. 4 P2 receptor antagonists partially block ATP- and UTP-
mediated ERK1/2 phosphorylation. BACCs were pretreated with or
without suramin (100 μM) or reactive blue 2 (RB2, 100 μM) for 15
min, followed by a 10-min stimulation with or without ATP (100 μM)
or UTP (100 μM). Blots are representative of three independent
experiments performed in triplicate (n=3); the upper band (phosphor-
ylated or nonphosphorylated) is ERK1=44 kDa, and the lower band is
ERK2=42 kDa. Blot intensities were measured with the Odyssey
Imaging System; values are phosphorylated ERK2 intensity divided
by total ERK2 intensity. Bars on graph represent mean ± standard
error of the mean. *** p<0.001 vs. stimulator alone
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receptors are not involved in the increase in ERK1/2 in
response to nucleotide stimulation. First, UTP does not
activate P2X ion channels but potently increases ERK1/2
phosphorylation. Additionally, α,βmeATP, an agonist se-
lective for several P2X receptor subtypes, had no effect on
ERK1/2 phosphorylation. The P2Y receptor involved is
most likely either P2Y2 or P2Y4. UTP is highly selective
for two P2Y receptor subtypes P2Y2 and P2Y4 and weakly
effective on the P2Y6 receptor. The P2Y6 subtype can be
ruled out because of the subtypes activated by UTP; only
the P2Y2 and P2Y4 subtypes are also strongly activated by
ATP. The weak effect of ADP, UDP and 2-MeSATP
confirms this designation, as these agonists are specific
for P2 receptor subtypes other than the P2Y2 or P2Y4
subtypes [6]. There are no available agonists or antagonists
to distinguish between the P2Y2 and P2Y4 receptors. Even
so, suramin and RB2 are commonly used to characterize
these receptors in a given cell type, and their partial
effectiveness is not contradictory to results found in other
cell types for P2Y2 or P2Y4 receptors [20].
Nucleotides utilize multiple signaling pathways in
different cell types to bring about increases in ERK1/2
phosphorylation. PKC and PI3K have been implicated in
P2Y-mediated ERK1/2 phosphorylation [10, 11]. In PC12
cells, ERK1/2 phosphorylation in response to P2Y2
receptor activation has been shown to be both dependent
[9, 10] and independent [21] of the small tyrosine kinase
Pyk2. P2Y2 receptors have also been shown to contain an
integrin-binding domain, arginine-glycine-aspartic acid
(RGD), which is necessary for ERK1/2 activation in
astrocytes [22, 23]. Additionally, P2Y2 receptors contain
SH3-binding sites that associate with Src in astrocytoma
cells [24] and astrocytes [23]. Also, in PC12 cells P2Y2
receptors have been shown to require EGFR transactivation
to increase ERK1/2 phosphorylation [9].
Initially, we examined whether signaling pathways medi-
ated by protein kinases were involved in ATP-mediated
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Fig. 5 Tyrosine kinase inhibition decreases ATP- and UTP-mediated
ERK1/2 phosphorylation. BACCs were pretreated with PP2 (1 μM) or
dimethylsulfoxide(DMSO)for15min,followedbya10-minstimulation
with or without ATP (100 μM) or UTP (100 μM). Blots are
representative of three independent experiments performed in triplicate
(n=3); the upper band (phosphorylated or nonphosphorylated) is ERK1
=44 kDa, and the lower band is ERK2=42 kDa. Blot intensities were
measured with the Odyssey Imaging System; values are phosphorylated
ERK2 intensity divided by total ERK2 intensity. Bars on the graphs
represent mean ± standard error of the mean. *** p<0.001 vs.
stimulator alone
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Fig. 6 Nucleotide-mediated ERK1/2 phosphorylation is dependent on
EGFR transactivation. BACCs were pretreated with or without
AG1478 (2.6 μM) (a), GM6001 (2.5 μM) (b) and dimethylsulfoxide
(DMSO) for 15 min, followed by a 10-min stimulation with or without
ATP (100 μM) or UTP (100 μM). Blots are representative of three
independent experiments performed in triplicate (n=3); the upper
band (phosphorylated or nonphosphorylated) is ERK1=44 kDa ,and
the lower band is ERK2=42 kDa. Blot intensities were measured with
the Odyssey Imaging System; values are phosphorylated ERK2
intensity divided by total ERK2 intensity. Bars on the graphs represent
mean ± standard error of the mean. *** p<0.001 vs. stimulator alone
328 Purinergic Signalling (2008) 4:323–330ERK1/2 phosphorylation. Previous studies determined that
ATP-mediated stimulation of bovine chromaffin cells results
in increases in inositol phosphates [7], cAMP [8], and [Ca
2+]i
accumulation [7]. P2Y2 or P2Y4 receptors couple to Gq
to increase activation of PKC. Additionally, the observed
increases in cAMP may result in activation of PKA, whereas
increased [Ca
2+]i may result in activation of CaMKII.
However, inhibitors of each of these protein kinases had no
effect on ATP- or UTP-mediated ERK1/2 phosphorylation,
including the PKA inhibitors H89 and KT5720, PKC
inhibitors Bis-I and Ro-81–3220, or the CaMKII inhibitor
KN93. The PKC inhibitors Bis-I and Ro-81–3220 were
capable of blocking PMA-mediated ERK1/2 phosphoryla-
tion, suggesting PKC can couple to ERK1/2 phosphorylation
in these cells, and yet confirming the lack of involvement of
this pathway in ATP-mediated ERK1/2 phosphorylation. We
also examined the PI3K inhibitors wortmannin and
LY294002, as this kinase has been implicated in P2Y-
mediated ERK1/2 phosphorylation. These inhibitors also
proved to be ineffective, suggesting the protein kinases
examined were not responsible for ATP-mediated ERK1/2
phosphorylation.
We next examined the involvement of tyrosine kinases
in ATP-mediated ERK1/2 phosphorylation, as these kinases
have been shown to be involved in P2Y-mediated ERK1/2
phosphorylation. PP2 (1 μM) significantly decreased ATP-
and UTP-mediated ERK1/2 phosphorylation. The reported
IC50s for PP2-mediated inhibition of Src family members
are in the nanomolar range (http://www.biomol.com),
whereas the dose used in these studies is reported to cause
weak inhibition of the EGFR [25]. Lower doses of PP2 had
no effect on ATP- or UTP-mediated ERK1/2 phosphoryla-
tion (data not shown.) Therefore, at the effective dose used,
it is not possible to conclude whether Src or EGFR
inhibition was responsible for the decrease in ATP-
mediated ERK1/2 phosphorylation. Additionally, activation
of Src family members by G-protein-coupled receptors may
increase ERK1/2 phosphorylation via activation of the
renin angiotensin system (Ras) [17, 18] or via trans-
activation of the EGFR [26]. Thus, the involvement of
EGFR in ATP-mediated ERK1/2 phosphorylation was
investigated further. Inhibition of the EGFR with the
specific inhibitor AG1478 decreased ATP- and UTP-
mediated ERK1/2 phosphorylation, strongly suggesting
EGFR transactivation is important for ATP-mediated
ERK1/2 phosphorylation.
G-protein-coupled receptors may transactivate the EGFR
via activation of tyrosine kinases such as Src, or via
activation of metalloproteinases to generate EGFR ligands
such as HB-EGF [19]. The role of metalloproteinases in
ATP-mediated ERK1/2 phosphorylation was investigated
with broad-spectrum inhibitor GM6001, which significantly
decreased the response, suggesting that HB-EGF cleavage
mediated by metalloproteinases in response to ATP may be
responsible for transactivation of the EGFR and subse-
quently stimulation of ERK1/2 phosphorylation.
As expected, the MEK inhibitor PD98059 blocked ATP-
and UTP-mediated ERK1/2 phosphorylation, confirming
that MEK, the only known kinase upstream of ERK1/2,
contributes to ERK1/2 phosphorylation. PD98059 blocked
ATP-mediated ERK1/2 phosphorylation (∼90%) to a
greater extent than UTP-mediated ERK1/2 phosphorylation
(∼70%). This may be due to the fact that UTP is a more
potent agonist and elicited a larger response than ATP for
ERK1/2 phosphorylation. For the other inhibitors, the
responses were very similar; however, none of the other
inhibitors had such a pronounced effect on ATP-mediated
ERK1/2 phosphorylation. Alternatively, ATP and UTP may
activate multiple receptors with distinct signaling pathways
that are variously more specific for ATP or UTP. Activation
of ERK1/2 independent of MEK1 may involve inhibition of
phosphatases.
Further studies are necessary to determine the conse-
quence(s) of ERK1/2 phosphorylation in response to ATP
stimulation of chromaffin cells. As chromaffin cells are
nonproliferating, the stimulation of ERK1/2 phosphoryla-
tion by ATP and UTP may couple to regulation of gene
transcription essential to exocytosis.
To our knowledge this is the first study demonstrating
phosphorylation of ERK1/2 in response to ATP or UTP
stimulation in bovine chromaffin cells. Our data show that
the ERK1/2 phosphorylation response to ATP is mediated
by either a P2Y2 or P2Y4 receptor. Protein kinases are not
involved in nucleotide-mediated ERK1/2 phosphorylation,
but rather, metalloproteinase-dependent transactivation of
the EGFR is necessary for ATP-mediated ERK1/2 phos-
phorylation.
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